Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Retained Earnings (2021 - 2025)

Historic Retained Earnings for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to -$27.2 million.

  • Krystal Biotech's Retained Earnings rose 8795.61% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.2 million, marking a year-over-year increase of 8795.61%. This contributed to the annual value of -$180.7 million for FY2024, which is 3304.3% up from last year.
  • Latest data reveals that Krystal Biotech reported Retained Earnings of -$27.2 million as of Q3 2025, which was up 8795.61% from -$106.6 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Retained Earnings registered a high of -$27.2 million during Q3 2025, and its lowest value of -$359.3 million during Q2 2023.
  • Its 5-year average for Retained Earnings is -$201.6 million, with a median of -$218.9 million in 2022.
  • In the last 5 years, Krystal Biotech's Retained Earnings tumbled by 11918.62% in 2022 and then skyrocketed by 8795.61% in 2025.
  • Over the past 5 years, Krystal Biotech's Retained Earnings (Quarter) stood at -$140.8 million in 2021, then tumbled by 99.43% to -$280.8 million in 2022, then rose by 3.89% to -$269.8 million in 2023, then skyrocketed by 33.04% to -$180.7 million in 2024, then skyrocketed by 84.92% to -$27.2 million in 2025.
  • Its Retained Earnings was -$27.2 million in Q3 2025, compared to -$106.6 million in Q2 2025 and -$144.9 million in Q1 2025.